- Home
- ZEPP vs NBP Comparison
ZEPP vs NBP Comparison
Compare ZEPP & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$13.84
N/A
Current Price
$2.56
Company Overview
Basic Information| Metric | ZEPP | NBP |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Netherlands | United States |
| Employees | N/A | 32 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.7M | 379.3M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZEPP | NBP |
|---|---|---|
| Price | $13.84 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 121.4K | ★ 919.8K |
| Earning Date | 05-18-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $778.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $2.10 |
| 52 Week High | $61.50 | $5.19 |
Technical Indicators
Market Signals| Indicator | ZEPP | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 44.92 |
| Support Level | $10.51 | $2.10 |
| Resistance Level | $15.85 | $3.80 |
| Average True Range (ATR) | 1.25 | 0.22 |
| MACD | 0.47 | 0.03 |
| Stochastic Oscillator | 72.55 | 67.91 |
Price Performance
Historical Comparison ZEPP
NBP
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.